Harvard Infectious Diseases in Adults 2021 | Medical Video Courses.

Harvard Infectious Diseases in Adults 2021

Regular price
Sale price
Regular price
Sold out
Unit price

Harvard Infectious Diseases in Adults 2021

By Harvard Medical School 2021


Infectious Diseases in Adults will be held online this year, using live streaming, electronic Q&A, and other remote learning technologies. 


This comprehensive CME program ensures attendees are current with state-of-the-art approaches to prevention, detection, diagnosis, and treatment of infectious diseases. Updates, best practices, and new guidelines are presented by nationally recognized ID experts and master clinicians. Education is practical and results driven:

  • Optimal decision-making in the prevention, diagnosis, and treatment of infectious diseases
  • Newer antimicrobials and treatment strategies for highly resistant infections
  • COVID-19: the latest updates
  • Prevention and treatment of infection in immunocompromised hosts
  • State-of-the-art approaches to common infections
  • Clinical approaches to complex, rare, “don’t-miss” infections
  • New, evolving, and emerging infectious diseases
  • Update on antifungal diagnostics and therapy
  • Optimal management of Staph aureus infections
  • Infections in persons with substance use disorder
  • What’s new in HIV prevention and management
  • Musculoskeletal infectious diseases

As revised treatment strategies, new diagnostic tests, and guidelines are presented, they are coupled with specific recommendations for incorporating these updates into your day-to-day work.

Highlights of the 2021 Program

Expanded Case-Based and Problem-Solving Education 

The 2021 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions of our national experts in Q and A sessions following the lectures and the workshops.

Treating Highly Resistant Infections, including:

  • MRSA and VISA (vancomycin-intermediate Staph aureus)
  • Extended spectrum beta-lactamase (ESBL)-producing gram negative rods
  • Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms
  • Vancomycin-resistant enterococci (VRE)
  • Aspergillus and  non-aspergillus mold infections
  • Candida auris
  • Nontuberculous mycobacteria (NTM)

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

  • Infections in the expanding populations of immunocompromised hosts
  • Infections in persons with substance use disorders
  • Infections of travelers and foreign-born persons
  • Systemic fungal infections
  • Native and device-related orthopedic infections
  • Central nervous system (CNS) infections
  • Ear, nose and throat (ENT) and eye infections
  • Bronchiectasis and pneumonia
  • HIV and its infectious and noninfectious complications
  • PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection
  • Sexually transmitted infections
  • Hepatitis B and C infections
  • Tick- and mosquito-borne infections
  • Vaccines and vaccine-preventable infections
  • Clostridioides difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

  • COVID-19
  • EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases
  • Re-emergence of vaccine-preventable diseases
  • Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus
  • Global infectious diseases of clinical importance

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

  • Selecting the best antimicrobial and duration of treatment
  • Rapid detection and empiric treatment of the life-threatening infectious diseases
  • Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral?
  • Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop

Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

  • Antimicrobial stewardship to prevent resistance and reduce cost
  • Infection control, including biothreats
  • Early inpatient ID consultations to improve outcomes


Sold Out